Sociodemographic factors tied to the development and nonrecovery from long COVID. HealthDay News — The majority of working-age patients with post-acute sequelae of COVID-19/post-COVID-19 ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

In the United States, hyperlipidemia-related CVD mortality increased from 1999 to 2019, with elderly, Black, rural men being most affected. Hyperlipidemia-related cardiovascular disease (CVD ...

The negative effects of climate change are increasingly being experienced throughout healthcare, with impacts on individual patients, clinicians, organizational operations, and public health as a ...

The cancer death rate decreased 34% from 1991 through 2022. Though the rate of cancer death is declining in the United States, cancer incidence is rising among US women, according to a report from ...

One of those now-canceled policies directed Medicare to investigate ways to slash drug costs, including the possibility of a $2 monthly out-of-pocket cap on some generic medications. HealthDay ...

The prescription of high dose was associated with an increased risk of TD, and the highest risk was observed in the group receiving >300 mg/day. HealthDay News — Antipsychotics at doses >75 mg ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...

Leukocyte count linked to severity of post-acute sequelae of SARS-CoV-2 infection, but not of PASC occurrence or related cognitive outcomes ...

Secretary of State Marco Rubio announced the waiver on Tuesday; however, exactly what it covers remains unclear. While the waiver does allow for the resumption of distributing HIV medications, the ...

Findings showed acalabrutinib with bendamustine and rituximab (BR) reduced the risk of disease progression or death by 27% compared with placebo plus BR. The Food and Drug Administration (FDA) has ...

Tetrahydrocannabinol test results do not impact the probability of a patient having a short or long length of stay at the epilepsy monitoring unit. Tetrahydrocannabinol (THC) positivity does not ...